The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

NCT02792400 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: LY2403021
DRUG: LY2403021 placebo
PROCEDURE: Standardised liquid meal
DRUG: Linagliptin
DRUG: Linagliptin placebo
DRUG: Empagliflozin
DRUG: Empagliflozin placebo

Sponsor

University Hospital, Gentofte, Copenhagen

Collaborators

[object Object]